English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

NETs NETs are relatively rare and encompass a heterogeneous group of tumors with an incidence of approximately 7.0 in 100,000 (1,2), although it is increasing. The most common type is gastroenteropancreatic NETs, which are broken down by sites of origin into gastric, pancreatic, small bowel, colorectal, and those of unknown origin. In addition to gastroenteropancreatic NETs, there are many subtypes of NETs, including pheochromocytomas, paragangliomas, medullary thyroid cancer, Merkel cell cancer, and bronchial carcinoids. Given the lack of evidence in other disease subtypes, these AUC will focus on the role of SSTR PET in well-differentiated gastroenteropancreatic NETs. The belief is that SSTR PET will be valuable in many SSTR-positive diseases beyond gastroenteropancreatic NETs, although these other diseases are not covered in the clinical scenarios in this document.

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors